- Report
- October 2023
- 173 Pages
Global
From €3967EUR$4,500USD£3,485GBP
- Report
- October 2023
- 150 Pages
Global
From €3394EUR$3,850USD£2,981GBP
€4276EUR$4,850USD£3,756GBP
- Report
- May 2024
- 124 Pages
Global
From €3482EUR$3,950USD£3,059GBP
- Report
- May 2024
- 250 Pages
Global
From €4404EUR$4,995USD£3,868GBP
- Report
- October 2025
- 94 Pages
Saudi Arabia
From €4276EUR$4,850USD£3,756GBP
- Report
- June 2023
- 112 Pages
Global
From €3500EUR$4,253USD£3,182GBP
Polyclonal antibodies are a type of immune disorder drug used to treat a variety of conditions, including autoimmune diseases, allergies, and cancer. These drugs are made up of a mixture of antibodies that are produced by the body in response to a foreign substance, such as a virus or bacteria. They work by targeting and neutralizing the foreign substance, thus preventing it from causing further damage. Polyclonal antibodies can be administered intravenously, intramuscularly, or subcutaneously.
Polyclonal antibodies are used to treat a variety of conditions, including rheumatoid arthritis, multiple sclerosis, Crohn's disease, and psoriasis. They are also used to treat certain types of cancer, such as lymphoma and leukemia. In addition, polyclonal antibodies are used to treat allergies, such as hay fever and asthma.
The polyclonal antibodies market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more